LESLIE YEARTA-BROWN: Open Payments
NPI 1225378524 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$647 in 20 payments from 10 companies in 2025. Trend: 2023 $592 · 2024 $688 · 2025 $647
Food & beverage: $647
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 2 | $152 |
| Travere Therapeutics, Inc. | 3 | $145 |
| AstraZeneca Pharmaceuticals LP | 5 | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $48 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $38 |
| Ardelyx, Inc. | 1 | $33 |
| GENZYME CORPORATION | 1 | $32 |
| Vantive US Healthcare LLC | 1 | $29 |
| SCPHARMACEUTICALS INC. | 1 | $15 |
| GlaxoSmithKline, LLC. | 1 | $15 |
Products named: TARPEYO, Filspari, FARXIGA, JARDIANCE, LOKELMA, IBSRELA, FABRAZYME, Renal - PD.
Industry payments across MO — which companies pay providers there.
